FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
查看参考文章
作者
相关见解
December 19, 2025
Foley Viewpoints
Prohibition to Prescription: What Trump’s Marijuana Executive Order Really Means
On December 18, 2025, President Donald Trump issued an Executive Order, Increasing Medical Marijuana and Cannabidiol Research, that…
2025年12月18日
福莱观点
美国保险监督官协会就人工智能行政命令发表声明
2025年12月16日,美国保险监管官协会(NAIC)就12月……发布声明(NAIC声明)。
2025年12月18日
福莱观点
企业如何应对纽约州新出台的算法定价规则
各州正竞相限制人工智能和计算机算法在定价领域的日益普及,纽约州率先采取行动。12月15日,纽约州反垄断法一项重大修订正式生效,根据该州《一般商业法》第340-b条,禁止在住宅单元定价中使用特定算法工具。